OakChart

First Tracks Biotherapeutics Inc

TRAXHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 10:12 AM ET

51.81-0.52 (-0.98%)
2026-11-11 16:13 CET
Market cap
2,198.80 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-31.36 USD m
Free cash flow, TTM
-17.05 USD m
EPS diluted, TTM
-0.87
P/E
-
Compare

Price

TRAX against its 20 and 50-day averages
2050beatmiss
20.0030.0040.0050.003.7M7.3MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26TRAXclose 51.8220-day 44.5250-day 39.7651.82

5.4% under 54.78 on 10 Nov 2026. Last 15 sessions, 31.7% high to low

Profile

TRAX
52-week range, 93% of the way up
14.7254.78

First Tracks Biotherapeutics, Inc. engages in the research and development of immunology therapeutics for autoimmune and inflammatory diseases. It focuses on clinical-stage programs for rosnilimab, ANB033 and ANB101. The company is headquartered in San Diego, CA.

IPOApr 06, 2026
ATR, 14d3.27
Rel volume0.39
Short float14.10%
Insider own14.67%
Inst own76.79%

Snapshot

6 groups

Valuation

Index-
Market Cap2.18B
Enterprise Value2.03B
Income-
Sales-
Book/sh4.21
Cash/sh3.70
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees-
IPOApr 06, 2026

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B12.32
P/C13.99
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio9.16
Current Ratio9.16
Debt/Eq0.02
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-
EPS next Y-3.55
EPS next Q-0.75
EPS this Y28.22%
EPS next Y12.06%
EPS next 5Y11.66%
EPS past 3/5Y- -
Sales past 3/5Y- -
EPS Y/Y TTM-
Sales Y/Y TTM-
EPS Q/Q27.17%
Sales Q/Q-
EarningsNov 03 AMC
EPS/Sales Surpr.2.51% -

Ownership

Insider Own14.67%
Insider Trans-0.63%
Inst Own76.79%
Inst Trans201.45%
ROA-
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2016.38%
SMA5030.30%
SMA20064.52%
Trades-

Technical

Shs Outstand35.90M
Shs Float35.85M
Short Float14.10%
Short Ratio6.07
Short Interest5.06M
52W High54.78 -5.41%
52W Low14.72 252.00%
Volatility8.84% 8.03%
ATR (14)3.27
RSI (14)69.66
Beta-
Rel Volume0.39
Avg Volume833.25K
Volume49,378

Performance

Perf Week5.66%
Perf Month63.56%
Perf Quarter17.68%
Perf Half Y181.14%
Perf YTD159.07%
Perf Year-
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.08
Target Price74.75
Prev Close52.33
Price51.81
Change %-0.98%

Analyst ratings

latest 10 of 12
DateActionAnalystRating changeTargetImplied
Sep 30, 2026InitiatedCCanaccord GenuityBuy$50-3.5%
Sep 18, 2026InitiatedEEvercore ISIOutperform$65+25.4%
Sep 16, 2026InitiatedGGuggenheimBuy$100+93.0%
Aug 18, 2026InitiatedWWolfe ResearchOutperform$83+60.2%
Jun 08, 2026InitiatedWWells FargoOverweight$30-42.1%
May 04, 2026InitiatedPPiper SandlerOverweight$54+4.2%
Apr 28, 2026InitiatedHH.C. WainwrightBuy$30-42.1%
Apr 24, 2026InitiatedWWedbushOutperform$30-42.1%
Apr 24, 2026InitiatedLLeerink PartnersOutperform$46-11.2%
Apr 23, 2026InitiatedJJP MorganOverweight$31-40.2%

Peers

Mkt cap
TickerCompanyMkt cap
ANABAnaptysBio Inc1.46B
IMVTImmunovant Inc7.48B
ATTOAttovia Therapeutics Inc771.52M
SYRESpyre Therapeutics Inc9.92B
ALMSAlumis Inc868.39M
UPBUpstream Bio Inc184.58M
ETRAElectra Therapeutics Inc522.85M
ACRSAclaris Therapeutics Inc670.14M
ABVXAbivax ADR8.01B
KYMRKymera Therapeutics Inc11.65B

Insider trading

10 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Orwin John ADirectorSep 15 '26Option Exercise0.001,300017,995Sep 17 04:05 PM
Ware J. AnthonyDirectorSep 02 '26Option Exercise5.7439,265225,38154,925Sep 04 04:25 PM
Ware J. AnthonyDirectorSep 02 '26Sale44.7839,2651,758,14515,660Sep 04 04:25 PM
JOE ANTHONY WAREDirectorSep 02 '26Proposed Sale44.7839,2651,758,145Sep 02 04:12 PM
Jain RitaDirectorJun 15 '26Option Exercise0.007,330019,194Jun 17 04:05 PM
Schmid John P.DirectorJun 15 '26Option Exercise0.006,030037,652Jun 17 04:05 PM
Orwin John ADirectorJun 15 '26Option Exercise0.006,030016,695Jun 17 04:05 PM
Ware J. AnthonyDirectorJun 15 '26Option Exercise0.006,030015,660Jun 17 04:05 PM
Marquet MagdaDirectorJun 15 '26Option Exercise0.006,030015,960Jun 17 04:05 PM
FENTON DENNIS MDirectorJun 15 '26Option Exercise0.006,030010,995Jun 17 04:05 PM

Held by

AUM
TickerCompanyAUM
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VHTVanguard Health Care ETFAUM: 21.51B

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-03-0.880-0.903-0.8790.000.0010
2026Q22026-08-12-0.950-0.803-0.9430.000.008
2026Q4---0.754--0.0010
2027Q1---0.763--0.006
2027Q2---0.768--0.006
2027Q3---0.790--0.006
2027Q4---0.803--0.006

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2025FY-5.493--5.6170.00-
2026FY--4.032--0.00
2027FY--3.545--0.00
2028FY--3.873--0.00
2029FY--3.864--20.98
2030FY--4.497--32.90

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-047000.000.000.00
2026Q4S2026-11-036000.000.000.00
2026Q4S2026-09-296000.000.000.00
2026Q4S2026-09-155000.000.000.00
2026Q4S2026-08-134000.000.000.00
2026Q4S2026-07-314000.000.000.00
2026Q4S2026-07-205000.000.000.00
2026Q4S2026-05-156000.000.000.00
2026Q4S2026-05-016000.000.000.00
2026Q4S2026-04-275000.000.000.00
2026Q4S2026-04-234000.000.000.00
2026Q4S2026-04-222000.000.000.00
2026Q4S2026-04-111000.000.000.00
2026Q4R2026-11-04430-0.82-0.98-0.70

Estimate history

EPS, annual-4.692-4.76
Period20242025
EPS, quarterly-1.353-1.199-1.2-1.447-0.943-0.873
PeriodQ1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26
Sales, annual00
Period20242025
Sales, quarterly000000
PeriodQ1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26
Shares, annual34.89234.89235.902
Period20242025MRQ
Shares, quarterly34.89235.39134.89234.89235.39135.902
PeriodQ1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY
Total Revenue0.000.000.00
Cost of Goods Sold Incl. D&A0.992.422.40
Gross Profit-0.99-2.42-2.40
Selling, General and Administrative Excl. Other31.85176.58178.70
Research and Development23.75139.06151.74
Other Operating Expense0.000.000.00
Operating Income-32.84-179.01-181.10
Interest Expense0.000.000.00
Unusual Expense0.000.000.00
Net Income Before Taxes-31.36-166.09-163.71
Income Taxes0.000.000.00
Consolidated Net Income-31.36-166.09-163.71
Net Income From Continuing Operations-31.36-166.09-163.71
Net Income-31.36-166.09-163.71
EPS (Recurring)-0.87-4.76-4.69
EPS (Basic, Before Extraordinaries)-0.87-4.76-4.69
EPS (Diluted)-0.87-4.76-4.69
EBITDA-31.85-176.58-178.70
Non-Operating Income (Expense)1.4912.9217.40
Other After Tax Adjustments0.000.000.00
Stock Option Compensation Expense0.0032.3026.83
Shares Outstanding35.9034.8934.89
Market Capitalization2,198.802,198.80-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q32025Q22025Q1
Total Revenue0.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.990.210.120.610.600.61
Gross Profit-0.99-0.21-0.12-0.61-0.60-0.61
Selling, General and Administrative Excl. Other31.8534.7352.6944.4545.3050.67
Research and Development23.7525.5433.8333.1839.1341.32
Other Operating Expense0.000.000.000.000.000.00
Operating Income-32.84-34.94-52.81-45.06-45.90-51.28
Interest Expense0.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.00
Net Income Before Taxes-31.36-33.37-50.48-41.86-42.45-47.20
Income Taxes0.000.000.000.000.000.00
Consolidated Net Income-31.36-33.37-50.48-41.86-42.45-47.20
Net Income From Continuing Operations-31.36-33.37-50.48-41.86-42.45-47.20
Net Income-31.36-33.37-50.48-41.86-42.45-47.20
EPS (Recurring)-0.87-0.94-1.45-1.20-1.20-1.35
EPS (Basic, Before Extraordinaries)-0.87-0.94-1.45-1.20-1.20-1.35
EPS (Diluted)-0.87-0.94-1.45-1.20-1.20-1.35
EBITDA-31.85-34.73-52.69-44.45-45.30-50.67
Non-Operating Income (Expense)1.491.562.333.203.454.08
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense0.001.4711.509.857.667.75
Shares Outstanding35.9035.3934.8934.8935.3934.89
Market Capitalization2,198.801,285.59----

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY
Cash & Short Term Investments311.64385.37
Short Term Receivables0.000.00
Inventories0.000.00
Other Current Assets4.764.56
Total Current Assets316.40389.93
Net Property, Plant & Equipment13.8916.23
Total Investments and Advances0.0035.47
Other Assets0.260.26
Total Assets330.55441.89
Short Term Debt Incl. Current Port. of LT Debt2.081.93
Accounts Payable3.113.79
Other Current Liabilities25.8330.47
Total Current Liabilities31.0236.18
Long Term Debt12.0314.11
Provision for Risks Charges0.000.00
Other Liabilities0.000.00
Total Liabilities43.0550.30
Non-Equity Reserves0.000.00
Preferred Stock - Carrying Value0.000.00
Common Equity287.49391.60
Total Shareholders Equity287.49391.60
Accumulated Minority Interest0.000.00
Total Equity287.49391.60
Total Liabilities & Stockholders Equity330.55441.89
Book Value Per Share8.2411.22
Tangible Book Value Per Share8.2411.22
Price to Book Ratio12.44-
Return on Assets-43.00-
Return on Equity-48.91-
Return on Invested Capital-55.45-40.35
Quick Ratio10.2010.78
Current Ratio10.2010.78

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY
Net Income-31.36-166.09-163.71
Depreciation0.992.422.40
Other Funds (Non Cash)8.9027.5716.51
Funds from Operations-21.47-136.10-144.79
Extraordinary Item0.000.000.00
Changes in Working Capital4.42-6.8318.99
Cash from Operating Activities-17.05-142.93-125.81
Capital Expenditures0.00-0.09-0.36
Net Assets From Acquisitions0.000.000.00
Sale of Fixed Assets and Businesses0.000.000.00
Purchase or Sale of Investments0.00228.1295.76
Purchase of Investments0.00-196.41-380.38
Sale Or Maturity of Investments0.00424.53476.13
Other Uses0.000.000.00
Other Sources0.000.000.00
Cash from Investing Activities0.00228.0395.40
Cash Dividends Paid0.000.000.00
Preferred Dividends (Cash Flow)0.000.000.00
Change in Capital Stock4.6630.01117.52
Repurchase of Common Pref Stock0.000.000.00
Sale of Common Pref Stock4.6630.01117.52
Proceedsfrom Stock Options4.6630.01117.52
Issuance or Reduction of Debt, Net0.000.000.00
Change in Long Term Debt0.000.000.00
Issuance of Long Term Debt0.000.000.00
Reduction of Long Term Debt0.000.000.00
Net Financing Active Other Cash Flow0.000.000.00
Other Financing Activities Uses0.000.000.00
Cash from Financing Activities4.6630.01117.52
Net Change in Cash-12.39115.1287.11
Free Cash Flow-17.05-143.01-126.16
Deferred Taxes & Investment Tax Credit-0.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q32025Q22025Q1
Cash & Short Term Investments155.63168.02286.45---
Short Term Receivables2.870.000.00---
Inventories0.000.000.00---
Other Current Assets7.239.732.95---
Total Current Assets165.72177.75289.40---
Net Property, Plant & Equipment4.735.391.17---
Total Investments and Advances0.000.000.00---
Intangible Assets0.000.000.00---
Other Assets0.000.000.00---
Total Assets170.46183.14290.58---
Short Term Debt Incl. Current Port. of LT Debt2.422.440.00---
Accounts Payable3.952.557.50---
Other Current Liabilities11.727.4625.62---
Total Current Liabilities18.0912.4533.11---
Long Term Debt1.351.900.00---
Provision for Risks Charges0.000.000.00---
Other Liabilities0.000.000.00---
Total Liabilities19.4514.3433.11---
Non-Equity Reserves0.000.000.00---
Preferred Stock - Carrying Value0.000.000.00---
Common Equity151.01168.80257.46---
Total Shareholders Equity151.01168.80257.46---
Accumulated Minority Interest0.000.000.00---
Total Equity151.01168.80257.46---
Total Liabilities & Stockholders Equity170.46183.14290.58---
Book Value Per Share4.214.777.38---
Tangible Book Value Per Share4.214.777.38---
Price to Book Ratio12.447.54----
Return on Invested Capital-20.58-19.55-19.61---
Quick Ratio9.1614.288.74---
Current Ratio9.1614.288.74---

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q32025Q22025Q1
Net Income-31.36-33.37-50.48-41.86-42.45-47.20
Depreciation0.990.210.120.610.600.61
Other Funds (Non Cash)8.908.4611.498.716.066.08
Funds from Operations-21.47-24.70-38.86-32.53-35.78-40.51
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital4.42-7.226.301.84-2.85-4.50
Cash from Operating Activities-17.05-31.92-32.56-30.69-38.64-45.01
Capital Expenditures0.00-0.03-0.02-0.01-0.04-0.04
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.0035.00103.2936.4414.88
Purchase of Investments0.000.000.00-19.66-54.21-122.55
Sale Or Maturity of Investments0.000.0035.00122.9590.65137.43
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.00-0.0334.98103.2836.4014.85
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock4.66278.697.850.00-5.725.72
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock4.66278.697.850.00-5.725.72
Proceedsfrom Stock Options4.66278.697.850.00-5.725.72
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.00-327.200.00-7.06-46.390.00
Other Financing Activities Uses0.00-327.200.00-7.06-46.390.00
Cash from Financing Activities4.66-48.517.85-7.06-52.105.72
Net Change in Cash-12.39-80.4510.2765.53-54.34-24.44
Free Cash Flow-17.05-31.94-32.58-30.70-38.68-45.04

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3014.10%5.1M35.9M827.78K
2026-10-1522.71%7.0M30.6M842.26K
2026-09-3017.10%5.2M30.4M775.84K
2026-09-1514.82%4.5M30.4M769.82K
2026-08-3113.27%4.0M30.4M762.84K
2026-08-14-3.9M-733.43K
2026-07-31-4.0M-721.92K
2026-07-15-4.8M-662.38K
2026-06-30-3.9M-499.77K
2026-06-15-2.9M-432.95K
2026-05-29-3.9M-389.46K
2026-05-15-3.9M-393.51K
2026-04-30-4.0M-338.17K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call17.5033.0037.500.007.3440.000.000.972-0.1280.005
call20.0030.5035.000.006.5430.000.000.969-0.1270.006
call22.5028.0032.500.005.8560.000.000.964-0.1250.006
call25.0025.5030.000.005.2540.000.000.960-0.1230.007
call30.0020.5025.000.004.2280.000.000.949-0.1180.009
call35.0015.5020.0012.003.3657.000.000.934-0.1120.011
call40.0010.5015.507.052.77716.000.000.776-0.4670.025
call45.006.0010.504.272.0867.000.000.713-0.4070.028
call50.002.207.001.101.8416.000.000.613-0.3210.031
call55.000.204.401.901.70713.000.000.469-0.2990.033
call60.000.051.850.551.3662.000.000.292-0.2130.028
put17.500.002.550.004.4030.000.00-0.028-0.1260.005
put20.000.002.550.003.9100.000.00-0.031-0.1250.006
put22.500.002.551.103.4786.000.00-0.036-0.1230.006
put25.000.001.000.103.56214.000.00-0.059-0.1840.010
put30.000.002.000.202.4287.000.00-0.051-0.1150.009
put35.000.000.500.203.0792.000.00-0.147-0.3080.020
put40.000.002.609.503.4380.000.00-0.224-0.4630.025
put45.000.003.100.002.6270.000.00-0.287-0.4020.028
put50.000.104.400.001.8410.000.00-0.387-0.3160.031
put55.001.806.500.001.4640.000.00-0.531-0.2930.033
put60.005.6010.500.001.5930.000.00-0.708-0.2070.028

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-06SCHEDULE 13G/ASEC
2026-11-04424B3SEC
2026-11-04424B3SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-11-01SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-11-01SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-11-01SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-11-01SEC
2026-11-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-038-KCurrent report2026-11-03SEC
2026-10-29EFFECTEffectiveness filing by commission orderSEC
2026-10-27SCHEDULE 13G/ASEC
2026-10-26S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-10-208-KCurrent report2026-10-19SEC
2026-10-158-KCurrent report2026-10-15SEC
2026-10-138-KCurrent report2026-10-12SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-02144Filing for proposed sale of securities under Rule 144.SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-15SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-15SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-15SEC
2026-08-14SCHEDULE 13GSEC
2026-08-14SCHEDULE 13GSEC
2026-08-13424B3SEC
2026-08-13SCHEDULE 13GSEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-128-KCurrent report2026-08-12SEC
2026-08-073/A2026-04-20SEC
2026-08-073/A2026-04-20SEC
2026-08-073/A2026-04-20SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-09001.76M1
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
FMR LLC4.89%
GEODE CAPITAL MANAGEMENT, LLC2.34%
Sanofi2.30%
Connor, Clark & Lunn Investment Management Ltd.0.46%
DEUTSCHE BANK AG\0.45%
Bank of New York Mellon Corp0.24%
Nuveen, LLC0.19%
VICTORY CAPITAL MANAGEMENT INC0.18%
Russell Investments Group, Ltd.0.17%
DIMENSIONAL FUND ADVISORS LP0.17%

Funds

Fund% owned
Select Health Care Portfolio1.12%
VANGUARD RUSSELL 2000 INDEX FUND0.37%
Fidelity Extended Market Index Fund0.37%
Schwab U.S. Small-Cap ETF0.35%
Select Biotechnology Portfolio0.24%
VANGUARD HEALTH CARE INDEX FUND0.21%
Fidelity Total Market Index Fund0.14%
Strategic Advisers Fidelity U.S. Total Stock Fund0.14%
Fidelity Series Total Market Index Fund0.12%
Goldman Sachs Small Cap Growth Fund0.11%

OakChart. TRAX. Cached 15 minutes.

Some panels did not load: news.